Operon for Biosynthesis of Lipstatin, the Beta-Lactone Inhibitor of Human Pancreatic Lipase

Applied and Environmental Microbiology
2014.0

Abstract

<jats:title>ABSTRACT</jats:title> <jats:p> Lipstatin, isolated from <jats:named-content content-type="genus-species">Streptomyces toxytricini</jats:named-content> as a potent and selective inhibitor of human pancreatic lipase, is a precursor for tetrahydrolipstatin (also known as orlistat, Xenical, and Alli), the only FDA-approved antiobesity medication for long-term use. Lipstatin features a 2-hexyl-3,5-dihydroxy-7,10-hexadecadienoic-β-lactone structure with an <jats:italic>N</jats:italic> -formyl- <jats:sc>l</jats:sc> -leucine group attached as an ester to the 5-hydroxy group. It has been suggested that the α-branched 3,5-dihydroxy fatty acid β-lactone moiety of lipstatin in <jats:named-content content-type="genus-species">S. toxytricini</jats:named-content> is derived from Claisen condensation between two fatty acid substrates, which are derived from incomplete oxidative degradation of linoleic acid based on feeding experiments. In this study, we identified a six-gene operon ( <jats:italic>lst</jats:italic> ) that was essential for the biosynthesis of lipstatin by large-deletion, complementation, and single-gene knockout experiments. <jats:italic>lstA</jats:italic> , <jats:italic>lstB</jats:italic> , and <jats:italic>lstC</jats:italic> , which encode two β-ketoacyl–acyl carrier protein synthase III homologues and an acyl coenzyme A (acyl-CoA) synthetase homologue, were indicated to be responsible for the generation of the α-branched 3,5-dihydroxy fatty acid backbone. Subsequently, the nonribosomal peptide synthetase (NRPS) gene <jats:italic>lstE</jats:italic> and the putative formyltransferase gene <jats:italic>lstF</jats:italic> were involved in decoration of the α-branched 3,5-dihydroxy fatty acid chain with an N-formylated leucine residue. Finally, the 3β-hydroxysteroid dehydrogenase-homologous gene <jats:italic>lstD</jats:italic> might be responsible for the reduction of the β-keto group of the biosynthetic intermediate, thereby facilitating the formation of the unique β-lactone ring.

Knowledge Graph

Similar Paper

Operon for Biosynthesis of Lipstatin, the Beta-Lactone Inhibitor of Human Pancreatic Lipase
Applied and Environmental Microbiology 2014.0
Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. II. Chemistry and structure elucidation.
The Journal of Antibiotics 1987.0
Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity.
The Journal of Antibiotics 1987.0
Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity.
The Journal of Antibiotics 1987.0
The role of acyl-coenzyme A carboxylase complex in lipstatin biosynthesis of Streptomyces toxytricini
Applied Microbiology and Biotechnology 2010.0
Biosynthetic Origin of Hydrogen Atoms in the Lipase Inhibitor Lipstatin
Journal of Biological Chemistry 2000.0
Development and Optimization of a High-Throughput Screening Assay for Rapid Evaluation of Lipstatin Production by Streptomyces Strains
Current Microbiology 2018.0
Implication of mutagenesis and precursor supplementation towards the enhancement of lipstatin (an antiobesity agent) biosynthesis through submerged fermentation using Streptomyces toxytricini
3 Biotech 2018.0
Ostalactones A–C, β- and ε-Lactones with Lipase Inhibitory Activity from the Cultured Basidiomycete <i>Stereum ostrea</i>
Journal of Natural Products 2016.0
Identification and characterization of acetyl-CoA carboxylase gene cluster in Streptomyces toxytricini
The Journal of Microbiology 2009.0